Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.44 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.42 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.42 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.42 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.42 |
| ▸ | CCR5 | P51681 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5577820 | 0.88 | GAA (0.53) | ACHEGAAKDM4ELMNASIGMAR1 | |
| SCHEMBL5577483 | 0.87 | ACHE (0.49) | ACHEGAAKDM4ELMNASIGMAR1 | |
| SCHEMBL5577547 | 0.83 | ACHE (0.48) | ACHEGAAKDM4ELMNASIGMAR1 | |
| SCHEMBL5577546 | 0.83 | ACHE (0.47) | ACHEKDM4ESIGMAR1 | |
| SCHEMBL5577500 | 0.82 | SIGMAR1 (0.48) | ACHESIGMAR1DRD3CCR5 | |
| SCHEMBL5577698 | 0.81 | MEN1 (0.48) | ACHEGAAKDM4ELMNASIGMAR1 | |
| SCHEMBL5577751 | 0.81 | ACHE (0.47) | ACHEKDM4ESIGMAR1MCHR1 | |
| SCHEMBL5577410 | 0.81 | DRD4 (0.45) | ACHESIGMAR1CHRM1CHRM3DRD3 | |
| SCHEMBL5577526 | 0.80 | ACHE (0.49) | ACHESIGMAR1CHRM3CACNA1G | |
| SCHEMBL5577801 | 0.80 | ACHE (0.52) | ACHESIGMAR1DRD3CACNA1G |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070043079-A1 | Heterocyclic compound containing nitrogen atom and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-02-22 | — | — | US | disclosed |
| EP-1616862-A1 | NITROGENOUS HETEROCYCLIC COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-01-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043079-A1 | Heterocyclic compound containing nitrogen atom and use thereof | HLA-DRB1, MIF, HLA-C | ACHE 1504/4885GAA 3806/4885KDM4E 4213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.